搜索医生

Gerardo Colon-Otero, M.D.

  1. Hematologist
  2. Internist
  3. Oncologist
预约门诊

出版物

  1. Diaz-Cortes H, Hedges MS, Pacheco-Spann LM, Findley V, Leyva SC, Moran KM, DeStephano CC, Li Z, Colon-Otero G. A feasibility study assessing knowledge, vaccine hesitancy, and completion rates of free HPV vaccination in low-income uninsured adults. Prev Oncol Epidemiol. 2024; 2 (1) Epub 2024 May 12
    View PubMed
  2. Aslam FN, Manochakian R, Lou Y, Colon-Otero G, Sher T. Trends in participant race and sex reporting in lung cancer phase III clinical trials. Cancer Rep (Hoboken). 2023 Sep; 6 Suppl 1 (Suppl 1):e1856 Epub 2023 July 08
    View PubMed
  3. Jones JC, Golafshar MA, Coston TW, Rao R, Wysokinska E, Johnson E, Esplin ED, Nussbaum RL, Heald B, Klint M, Barrus K, Uson PL Jr, Nguyen CC, Colon-Otero G, Bekaii-Saab TS, Dronca R, Kunze KL, Samadder NJ. Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program. Cureus. 2023 Apr; 15 (4):e37428 Epub 2023 Apr 11
    View PubMed
  4. Kase AM, Azzouqa AG, Kochuveettil S, Colon-Otero G. Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review. Cancer Med. 2023 Apr; 12 (8):9434-9438 Epub 2023 Feb 21
    View PubMed
  5. Advani PP, Ruddy KJ, Herrmann J, Ray JC, Craver EC, Yothers G, Cecchini RS, Lipchik C, Feng H, Rastogi P, Mamounas EP, Swain SM, Geyer CE Jr, Wolmark N, Paik S, Pogue-Geile KL, Colon-Otero G, Perez EA, Norton N. Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial. Front Oncol. 2023; 13:1139347 Epub 2023 May 25
    View PubMed
  6. Valls ML, Kase AM, Patel R, Wang B, Aggarwal R, Colon-Otero G. Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report. Gynecol Oncol Rep. 2022 Jun; 41:101010 Epub 2022 May 25
    View PubMed
  7. Chumsri S, Li Z, Serie DJ, Norton N, Mashadi-Hossein A, Tenner K, Brauer HA, Warren S, Danaher P, Colon-Otero G, Partridge AH, Carey LA, Hilbers F, Van Dooren V, Holmes E, Di Cosimo S, Werner O, Huober JB, Dueck AC, Sotiriou C, Saura C, Moreno-Aspitia A, Knutson KL, Perez EA, Thompson EA. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer. 2022 May 24; 8(1):68.
    View PubMed
  8. Jaeckle KA, Dixon JG, Anderson SK, Moreno-Aspitia A, Colon-Otero G, Hebenstreit K, Patel TA, Reddy SL, Perez EA. Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Med. 2020 Nov; 9 (21):7935-7942 Epub 2020 Sept 03
    View PubMed
  9. Cordova-Ramirez AC, Sanchez-Valledor LF, Colon-Otero G, Rivera-Alvarez M, Elias-de-la-Cruz GD, Murrieta-Alvarez I, Cantero-Fortiz Y, Leon-Pena A, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Arguelles GJ. Mantle cell lymphoma may have a different clinical course in Mexican Mestizos: Real-world data from a single center. Rev Invest Clin. 2020 Oct 19; 73 (5) [Epub ahead of print]
    View PubMed
  10. Colon-Otero G, Zanfagnin V, Hou X, Foster NR, Asmus EJ, Wahner Hendrickson A, Jatoi A, Block MS, Langstraat CL, Glaser GE, Dinh TA, Robertson MW, Camoriano JK, Butler KA, Copland JA, Weroha SJ. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open. 2020 Oct; 5(5):e000926.
    View PubMed
  11. Reed DA, Harrison ME, Wolanskyj-Spinner AP, Dixon DA, Halyard MY, Colon-Otero G, Andresen-Reid ML, Meyer FB. Mayo Clinic Alix School of Medicine. Acad Med. 2020 Sep; 95 (9S A Snapshot of Medical Student):S262-S265
    View PubMed
  12. Rodriguez-Matta E, Hemmerich A, Starr J, Mody K, Severson EA, Colon-Otero G. Molecular genetic changes in solid pseudopapillary neoplasms (SPN) of the pancreas. Acta Oncol 2020 Sep; 59 (9):1024-1027 Epub 2020 July 16
    View PubMed
  13. Gonzalez-Mercado VJ, Lim J, Berk L, Esele M, Rodriguez CS, Colon-Otero G. Gut microbiota differences in Island Hispanic Puerto Ricans and mainland non-Hispanic whites during chemoradiation for rectal cancer: A pilot study. Curr Probl Cancer. 2020 Aug; 44 (4):100551 Epub 2020 Jan 27
    View PubMed
  14. McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Pancreatology. 2020 Jan; 20 (1):101-109 Epub 2019 Nov 21
    View PubMed
  15. Chumsri S, Li Z, Serie DJ, Mashadi-Hossein A, Colon-Otero G, Song N, Pogue-Geile KL, Gavin PG, Paik S, Moreno-Aspitia A, Perez EA, Thompson EA. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. J Clin Oncol. 2019 Dec 10; 37 (35):3425-3435 Epub 2019 Oct 17
    View PubMed
  16. Jorgensen MS, Velez-Velez LM, Asbun H, Colon-Otero G. Everolimus Is Effective Against Metastatic Solid Pseudopapillary Neoplasm of the Pancreas: A Case Report and Literature Review. JCO Precis Oncol. 2019 Dec; 3:1-6
    View PubMed
  17. Torres ME, Hashmi SK, Stevens MA, Tan AD, Callahan V, Sloan JA, Hogan WJ, Litzow MR, Roy V, Foran JM, Colon-Otero G. Impact of hospital hospitality house programs on quality of life and mood of patients and caregivers after hematopoietic stem cell transplant. Hematol Oncol Stem Cell Ther. 2019 Sep; 12 (3):155-160 Epub 2018 Dec 09
    View PubMed
  18. Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Farkkila A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Aug 1; 5 (8):1141-1149
    View PubMed
  19. Chumsri S, Serie DJ, Li Z, Pogue-Geile KL, Soyano-Muller AE, Mashadi-Hossein A, Warren S, Lou Y, Colon-Otero G, Knutson KL, Perez EA, Moreno-Aspitia A, Thompson EA. Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. Clin Cancer Res. 2019 Jul 15; 25 (14):4422-4430 Epub 2019 Feb 26
    View PubMed
  20. Gaillard SL, Andreano KJ, Gay LM, Steiner M, Jorgensen MS, Davidson BA, Havrilesky LJ, Alvarez Secord A, Valea FA, Colon-Otero G, Zajchowski DA, Chang CY, McDonnell DP, Berchuck A, Elvin JA. Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. Gynecol Oncol. 2019 Jul; 154 (1):199-206 Epub 2019 Apr 13
    View PubMed
  21. Mauras N, Torres-Santiago L, Santen R, Mericq V, Ross J, Colon-Otero G, Damaso L, Hossain J, Wang Q, Mesaros C, Blair IA. Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome. Clin Endocrinol (Oxf). 2019 Jan; 90 (1):155-161 Epub 2018 Oct 25
    View PubMed
  22. McWilliams RR, Wieben ED, Chaffee KG, Antwi SO, Raskin L, Olopade OI, Li D, Highsmith WE Jr, Colon-Otero G, Khanna LG, Permuth JB, Olson JE, Frucht H, Genkinger J, Zheng W, Blot WJ, Wu L, Almada LL, Fernandez-Zapico ME, Sicotte H, Pedersen KS, Petersen GM. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev. 2018 Nov; 27 (11):1364-1370 Epub 2018 July 23
    View PubMed
  23. Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Res. 2018 Jun 14; 20 (1):52 Epub 2018 June 14
    View PubMed
  24. Ailawadhi S, Frank RD, Sharma M, Menghani R, Temkit M, Paulus S, Khera N, Hashmi S, Advani P, Swaika A, Paulus A, Aslam N, Sher T, Roy V, Colon-Otero G, Chanan-Khan A. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. Cancer. 2018 Apr 15; 124 (8):1710-1721 Epub 2018 Jan 23
    View PubMed
  25. Ailawadhi S, Frank RD, Advani P, Swaika A, Temkit M, Menghani R, Sharma M, Meghji Z, Paulus S, Khera N, Hashmi SK, Paulus A, Kakar TS, Hodge DO, Colibaseanu DT, Vizzini MR, Roy V, Colon-Otero G, Chanan-Khan AA. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Med. 2017 Dec; 6 (12):2876-2885 Epub 2017 Nov 03
    View PubMed
  26. Serie DJ, Crook JE, Necela BM, Dockter TJ, Wang X, Asmann YW, Fairweather D, Bruno KA, Colon-Otero G, Perez EA, Thompson EA, Norton N. Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet Genomics. 2017 Oct; 27 (10):378-385
    View PubMed
  27. Gay LM, Kim S, Fedorchak K, Kundranda M, Odia Y, Nangia C, Battiste J, Colon-Otero G, Powell S, Russell J, Elvin JA, Vergilio JA, Suh J, Ali SM, Stephens PJ, Miller VA, Ross JS. Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. Oncologist. 2017 Jul; 22 (7):834-842 Epub 2017 May 11
    View PubMed
  28. Colon-Otero G, Weroha SJ, Foster NR, Haluska P, Hou X, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW, Copland JA. Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecol Oncol. 2017 Jul; 146(1):64-68. Epub 2017 Apr 28.
    View PubMed
  29. Serie DJ, Crook JE, Necela BM, Axenfeld BC, Dockter TJ, Colon-Otero G, Perez EA, Thompson EA, Norton N. Breast Cancer Clinical Trial of Chemotherapy and Trastuzumab: Potential Tool to Identify Cardiac Modifying Variants of Dilated Cardiomyopathy. J Cardiovasc Dev Dis. 2017 May 4; 4 (2) Epub 2017 May 04
    View PubMed
  30. Colon-Otero G, Van Wier SA, Ahmann GJ, Braggio E, Albertie ML, Weis JA, Ailawadhi S, Cerhan JR, Vishnu P, Jorgensen MS, Foran JM, Thomas CS, Fonseca R. Prevalence of BCL-2/J(H) Translocation in Healthy African Americans. Ann Hematol. 2017 Jan; 96 (1):51-55 Epub 2016 Oct 12
    View PubMed
  31. Radecki Breitkopf C, Finney Rutten LJ, Findley V, Jacobson DJ, Wilson PM, Albertie M, Jacobson RM, Colon-Otero G. Awareness and knowledge of Human Papillomavirus (HPV), HPV-related cancers, and HPV vaccines in an uninsured adult clinic population. Cancer Med. 2016 Nov; 5 (11):3346-3352 Epub 2016 Oct 17
    View PubMed
  32. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 Sep 10; 34 (26):3119-25 Epub 2016 June 06
    View PubMed
  33. Hall JC, Marlow LA, Mathias AC, Dawson LK, Durham WF, Meshaw KA, Mullin RJ, Synnott AJ, Small DL, Krishna M, von Hoff D, Schuler J, Hart SN, Couch FJ, Colon-Otero G, Copland JA. Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. J Transl Med. 2016 May 10; 14 (1):129
    View PubMed
  34. Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016 Mar; 15 (3):439-47 Epub 2016 Jan 28
    View PubMed
  35. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol. 2016 Feb 20; 34 (6):581-7 Epub 2015 Sept 21
    View PubMed
  36. Ailawadhi S, Advani P, Yang D, Ghosh R, Swaika A, Roy V, Foran J, Colon-Otero G, Chanan-Khan A. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis. Cancer. 2016 Feb 15; 122 (4):618-25 Epub 2015 Nov 13
    View PubMed
  37. Crozier JA, Sher T, Yang D, Swaika A, Foran J, Ghosh R, Tun H, Colon-Otero G, Kelly K, Chanan-Khan A, Ailawadhi S. Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. Clin Lymphoma Myeloma Leuk. 2015 Oct; 15 (10):578-85 Epub 2015 June 19
    View PubMed
  38. Mauras N, Santen RJ, Colon-Otero G, Hossain J, Wang Q, Mesaros C, Blair IA. Estrogens and Their Genotoxic Metabolites Are Increased in Obese Prepubertal Girls. J Clin Endocrinol Metab. 2015 Jun; 100 (6):2322-8 Epub 2015 Apr 09
    View PubMed
  39. Noriega-Iriondo MF, Colon-Otero G, Kipp BR, Copland JA, Ferber MJ, Marlow LA, Roberts ME, Robertson MW, Dinh TA, Attia S, Geiger XJ, Riegert-Johnson DL. High-grade endometrial stromal sarcoma as the initial presentation of an adult patient with Peutz-Jeghers Syndrome: a case report. Hered Cancer Clin Pract. 2015; 13 (1):6 Epub 2015 Jan 23
    View PubMed
  40. Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20; 32 (33):3744-52 Epub 2014 Oct 20
    View PubMed
  41. Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Erratum: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res. 2014 Nov 6; 16 (6):468 Epub 2014 Nov 06
    View PubMed
  42. Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res. 2014 Aug 1; 16 (4):419 Epub 2014 Aug 01
    View PubMed
  43. Colon-Otero G. Out of the woods, a Mayo Clinic emerges: a commentary on the history of Mayo Clinic in Florida. Mayo Clin Proc. 2014 May; 89(5):583-8.
    View PubMed
  44. Lesperance M, Shannon R, Pumphrey PK, Dunbar E, Genther R, Coleman CL, Tabano M, Maurer J, Vazquez A, Capp E, McMillan J, Wilkerson K, Robbins G, Phillips DG, Howick P, Solaun C, Sloan J, Colon-Otero G. Training mid-level providers on palliative care: bringing advanced directives and symptom assessment and management to community oncology practices. Am J Hosp Palliat Care. 2014 May; 31 (3):237-43 Epub 2013 Apr 23
    View PubMed
  45. Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol. 2014 Apr; 165: (1)78-88.
    View PubMed
  46. Colon-Otero G, Albertie M, Rodríguez J, Nicholson G, Kolomeyer I, Moreno-Aspitia A, Lesperance M, Perez EA. A Church-Based, Spanish-Language Community Education Breast Health Program Increases Awareness, Utilization of Breast Diagnostic Services Among Hispanics. Journal of Higher Education Outreach and Engagement.2014;18:(1):43-59.
  47. Moreno-Aspitia A, Dueck AC, Ghanem-Canete I, Patel T, Dakhil S, Johnson D, Franco S, Kahanic S, Colon-Otero G, Tenner KS, Rodeheffer R, McCullough AE, Jenkins RB, Palmieri FM, Northfelt D, Perez EA. RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat. 2013 Apr; 138 (2):427-35 Epub 2013 Mar 12
    View PubMed
  48. Colón-Otero G, Albertie M, Rodríguez J, Correa-Matos N, Nicholson G, Kolomeyer I, Moreno-Aspitia A, Lesperance L, Watson C, Perez EA. A Church-Based, Spanish-Language Community Education Breast Health Program Increases Awareness and Utilization of Breast Diagnostic Services among Hispanics. Journal of Higher Education Outreach and Engagement. 2013.
  49. Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, Menefee ME, Tun HW, Colon-Otero G, Perez EA, Copland JA. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. Mol Cancer Ther. 2012 Oct; 11 (10):2105-15 Epub 2012 July 23
    View PubMed
  50. Dyar S, Lesperance M, Shannon R, Sloan J, Colon-Otero G. A nurse practitioner directed intervention improves the quality of life of patients with metastatic cancer: results of a randomized pilot study. J Palliat Med. 2012 Aug; 15 (8):890-5 Epub 2012 May 04
    View PubMed
  51. Colon-Otero G, Albertie M, Lesperance M, Weis JA, Coles A, Smith N, Mills L, Woodward T, Aspitia AM, Vishnu P, Willis F, Isley A, Fonseca R, Vachon C, Rajkumar SV. A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans. J Cancer Educ. 2012 Jun; 27 (2):294-8
    View PubMed
  52. Vishnu P, Colon-Otero G, Kennedy GT, Marlow LA, Kennedy WP, Wu KJ, Santoso JT, Copland JA. RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer. Gynecol Oncol. 2012 Mar; 124 (3):589-97 Epub 2011 Nov 22
    View PubMed
  53. Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2012 Feb; 124 (2):210-5 Epub 2011 Nov 01
    View PubMed
  54. Armstrong MD, Von Hoff, Barber B, Marlow LA, von Roemeling, Cooper SJ, Travis P, Campbell E, Paz-Fumagalli R, Copland JA, Colon-Otero G. An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development. J Cancer. 2011; 2:142-52 Epub 2011 Mar 8.
    View PubMed
  55. Patel TA, Colon-Otero G, Bueno Hume C, Copland JA 3rd, Perez EA. Breast cancer in Latinas: gene expression, differential response to treatments, and differential toxicities in Latinas compared with other population groups. Oncologist. 2010; 15 (5):466-75 Epub 2010 Apr 28
    View PubMed
  56. Palmieri FM, DePeri ER, Mincey BA, Smith JA, Wen LK, Chewar DM, Abaya R, Colon-Otero G, Perez EA. Comprehensive diagnostic program for medically underserved women with abnormal breast screening evaluations in an urban population. Mayo Clin Proc. 2009 Apr; 84 (4):317-22
    View PubMed
  57. Zubair AC, Grant R, Wu W, Tun H, Rivera C, Moreno-Aspitia A, Joyce M, Roy V, Colon-Otero G, Solberg LA. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion. 2008 Jun; 48 (6):1106-14 Epub 2008 Feb 25
    View PubMed
  58. Colon-Otero G, Smallridge RC, Solberg LA Jr, Keith TD, Woodward TA, Willis FB, Dunn AN. Disparities in participation in cancer clinical trials in the United States : a symptom of a healthcare system in crisis. Cancer. 2008 Feb 1; 112(3):447-54.
    View PubMed
  59. Colon-Otero G, King S, Smith V, Bieber C, Crook J, Solberg LA, Shannon R, Perez EA. Increased incidence of loco-regional recurrences among african american women with terminal stage breast cancer. Clin Med Oncol. 2008; 2:547-50 Epub 2008 Nov 03
    View PubMed
  60. Moreno-Aspitia A, Colon-Otero G, Hoering A, Tefferi A, Niedringhaus RD, Vukov A, Li CY, Menke DM, Geyer SM, Alberts SR, North Central Cancer Treatment Group. Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer. 2006 Aug 15; 107(4):767-72.
    View PubMed
  61. Shannon RP, Gwin DK, Colon-Otero G, Howick PH. The palliative care consultation service: optimizing quality of life when quantity of life is limited. Northeast Florida Medicine. 2006; 57(4):35-9.
  62. Young PM, Paz-Fumagalli R, Colon-Otero G, Sevin BU. Postoperative pseudoaneurysm after debulking surgery for ovarian cancer: Long-term success of percutaneous thrombin injection. J Gynecol Surg. 2006; 22(2):77-80.
  63. Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A, Litzow MR, Roy V, Hogan WJ, Kyle RA, Gertz MA. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood. 2004 Nov 15; 104 (10):3400-7 Epub 2004 July 27
    View PubMed
  64. Colon-Otero G, Davis TH, Elkins S, Kosty MP, Mudad R, Niell HB, Wozniak AJ. Oncology Board Review study guide. American Journal of Oncology Review. 2004 Nov; 3(11 Suppl 10):1-20.
  65. Andrews TR, Colon-Otero G, Calamia KT, Menke DM, Boylan KB, Kyle RA. Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy. Mayo Clin Proc. 2002 Dec; 77(12):1287-90.
    View PubMed
  66. Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002 May 15; 99 (10):3854-6
    View PubMed
  67. Kumar S, Menke DM, Dewald GW, Colon-Otero G. Agnogenic myeloid metaplasia associated with Klinefelter syndrome: a case report. Ann Hematol. 2002 Apr; 81(4):215-8. Epub 2002 Mar 07.
    View PubMed
  68. Kuriakose P, Colon-Otero G, Paz-Fumagalli R. Risk of deep venous thrombosis associated with chest versus arm central venous subcutaneous port catheters: a 5-year single-institution retrospective study. J Vasc Interv Radiol. 2002 Feb; 13 (2 Pt 1):179-84
    View PubMed
  69. Colon-Otero G, Niedringhaus RD, Hillman SH, Geyer S, Sloan J, Geyer S, Sloan J, Krook JE, Windschitl HE, Marks RS, Wiesenfeld M, Tschetter LK, Jett JJ, North Central Cancer Treatment Group. A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs: a North Central Cancer Treatment Group Trial. Am J Clin Oncol. 2001 Dec; 24 (6):551-5
    View PubMed
  70. Menke DM, Griesser H, Moder KG, Tefferi A, Luthra HS, Cohen MD, Colon-Otero G, Lloyd RV. Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol. 2000 Feb; 113(2):212-8.
    View PubMed
  71. McLaughlin MP, Sevin BU, Colon-Otero G, Pettit PDM. Radiosensitizing approaches to patients with advanced cervical cancer. Cancer Research, Therapy & Control. 2000; 10(4):279-285.
  72. Moreno A, Moreno A, Colon-Otero G, Solberg LA Jr. The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard? Oncologist. 2000; 5 (3):238-49
    View PubMed
  73. Colon-Otero G, Moreno A, Tefferi A. A critical review of new treatments for the myelodysplastic syndromes. Cancer Research, Therapy & Control. 1999; 9(3-4):281-88.
  74. O'Connell MJ, Nagorney DM, Bernath AM, Schroeder G, Fitzgibbons RJ, Mailliard JA, Burch P, Bolton JS, Colon-Otero G, Krook JE. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol. 1998 Jul; 16: (7)2528-33.
    View PubMed
  75. Kyle RA, Colon-Otero G, Shampo MA. Jaime Ferran y Clua: bacteriologist. Mayo Clin Proc.. 1998 Apr; 63: (4)418.
  76. Colon-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Cancer J Sci Am. 1997 Sep-Oct; 3(5):297-302.
    View PubMed
  77. Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, Marschke RF, Windschitl HE. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol. 1995 Aug; 13: (8)2012-5.
    View PubMed
  78. Schild SE, Wharen RE Jr, Menke DM, Folger WN, Colon-Otero G. Primary lymphoma of the spinal cord. Mayo Clin Proc. 1995 Mar; 70 (3):256-60
    View PubMed
  79. Perniciaro C, Kuechle MK, Colon-Otero G, Raymond MG, Spear KL, Pittelkow MR. Paraneoplastic pemphigus: a case of prolonged survival. Mayo Clin Proc. 1994 Sep; 69 (9):851-5
    View PubMed
  80. Menke DM, Greipp PR, Colon-Otero G, Solberg LA Jr, Cockerill KJ, Hook CC, Witzig TE. Bone marrow aspirate immunofluorescent and bone marrow biopsy immunoperoxidase staining of plasma cells in histologically occult plasma cell proliferative marrow disorders. Arch Pathol Lab Med. 1994 Aug; 118(8):811-4.
    View PubMed
  81. Colon-Otero G, Malkasian GD, Edmonson JH. Secondary myelodysplasia and acute leukemia following carboplatin-containing combination chemotherapy for ovarian cancer. J Natl Cancer Inst. 1993 Nov 17; 85 (22):1858-60
    View PubMed
  82. Edmonson JH, Hartmann LC, Long HJ, Colon-Otero G, Fitch TR, Jefferies JA, Braich TA, Maples WJ. Granulocyte-macrophage colony-stimulating factor. Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin. Cancer. 1992 Nov 15; 70 (10):2529-39
    View PubMed
  83. Menke DM, Colon-Otero G, Cockerill KJ, Jenkins RB, Noel P, Pierre RV, Noel P. Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am J Clin Pathol. 1992 Nov; 98 (5):502-10
    View PubMed
  84. Colon-Otero G, Menke D, Menke D, Hook CC. A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia. Med Clin North Am. 1992 May; 76 (3):581-97
    View PubMed
  85. Solberg LA Jr. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group. Am J Med. 1992 Jan; 92 (1):69-76
    View PubMed
  86. Colon-Otero G, Cockerill KJ, Bowie EJ. How to diagnose bleeding disorders. Postgrad Med. 1991 Sep 1; 90 (3):145-50
    View PubMed
  87. Edmonson JH, Long HJ, Jeffries JA, Buckner JC, Colon-Otero G, Fitch TR. Amelioration of chemotherapy-induced thrombocytopenia by GM-CSF: apparent dose and schedule dependency. J Natl Cancer Inst 1989 Oct 4; 81 (19):1510-2
    View PubMed
  88. Kyle RA, Colon-Otero G, Shampo MA. Jaime Ferran y Clua: bacteriologist. Mayo Clin Proc. 1988 Apr; 63(4):418.
    View PubMed
  89. Colon-Otero G, Sando JJ, Sims JL, McGrath E, Quesenberry PJ. Inhibition of hemopoietic growth factor-induced proliferation by ADP-ribosylation inhibitors. Blood. 1987 Sep; 70:686-693.
    View PubMed
  90. Colon-Otero G, Gilchrist GS, Holcomb GR, Ilstrup DM, Bowie EJ. Preoperative evaluation of hemostasis in patients with congenital heart disease. Mayo Clin Proc. 1987 May; 62(5):379-85.
    View PubMed
  91. Colon-Otero G, McClure SP, Phyliky RL, White WL, Banks PM. Peripheral T-cell lymphoma simulating Hodgkin's disease with initial bone marrow involvement. Mayo Clin Proc. 1986 Jan; 61(1):68-71.
    View PubMed
  92. Colon-Otero G, Li CY, Dewald GW, White WL. Erythrophagocytic acute lymphocytic leukemia with B-cell markers and with a 20q- chromosome abnormality. Mayo Clin Proc. 1984 Oct; 59(10):678-82.
    View PubMed
  93. Kempson SA, Colon-Otero G, Ou SY, Turner ST, Dousa TP. Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest. 1981 May; 67(5):1347-60.
    View PubMed
PST-20218165